Viral hepatitis in haemophilia: historical perspective and current management

Cas J Isfordink; Karel J van Erpecum; Marc van der Valk; Evelien P Mauser-Bunschoten; Michael Makris

doi:10.1111/bjh.17438

Viral hepatitis in haemophilia: historical perspective and current management

Br J Haematol. 2021 Oct;195(2):174-185. doi: 10.1111/bjh.17438. Epub 2021 May 6.

Authors

Cas J Isfordink^{1

2

3}, Karel J van Erpecum², Marc van der Valk³, Evelien P Mauser-Bunschoten¹, Michael Makris^{4

5}

Affiliations

¹ Van Creveldkliniek, Department of Benign Haematology, University Medical Center Utrecht, Utrecht, the Netherlands.
² Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
³ Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
⁴ Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
⁵ Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

PMID: 33955555
DOI: 10.1111/bjh.17438

Abstract

The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.

Keywords: HBV; HCV; HIV; haemophilia; hepatitis C.

Publication types

Review

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents / therapeutic use
Blood Coagulation Factors / therapeutic use
Blood-Borne Infections / etiology
Blood-Borne Infections / prevention & control*
Blood-Borne Infections / transmission
Carcinoma, Hepatocellular / complications
Carcinoma, Hepatocellular / epidemiology
Disease Management
HIV / isolation & purification
HIV Infections / drug therapy
HIV Infections / epidemiology
HIV Infections / prevention & control*
HIV Infections / transmission
Hemophilia A / complications
Hemophilia A / epidemiology
Hemophilia A / therapy*
Hepatitis, Viral, Human / complications
Hepatitis, Viral, Human / drug therapy
Hepatitis, Viral, Human / prevention & control*
Hepatitis, Viral, Human / transmission
Humans
Liver Neoplasms / pathology
Liver Transplantation / adverse effects
Middle Aged
Morbidity / trends
Mortality / trends
Persistent Infection
Vaccination / methods
Young Adult

Substances

Antiviral Agents
Blood Coagulation Factors